China overtakes U.S. as leading venue for clinical trials, raising security concerns

A Senate Health Committee report and House Science Subcommittee hearing highlight that China has become the world's leading venue for clinical trials, noted for speed but with less rigorous safety work and less diverse patient enrollment. The article notes China has not yet produced a first-in-class clinically superior asset, and flags that up to 90% of widely used U.S. medications rely on China-sourced ingredients, prompting national security concerns and tariffs.

Why it matters. The shift in clinical trial leadership affects global drug development speed, regulatory standards, and national security due to reliance on China for pharmaceutical ingredients and genomic data, with implications for U.S. medical supply…